Detalhe da pesquisa
1.
Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib.
Value Health
; 26(2): 193-203, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36229359
2.
Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis.
Value Health
; 25(6): 984-991, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35667786
3.
The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis.
Value Health
; 25(8): 1428-1438, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35248467
4.
Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis.
Value Health
; 24(11): 1612-1619, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34711361
5.
Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands.
Mol Diagn Ther
; 28(3): 319-328, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38616205
6.
How microsimulation translates outcome estimates to patient lifetime event occurrence in the setting of heart valve disease.
Eur J Cardiothorac Surg
; 65(3)2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38515198
7.
Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model.
Mult Scler J Exp Transl Clin
; 9(3): 20552173231189398, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37529628
8.
Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.
Mult Scler Relat Disord
; 80: 105100, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37944195
9.
Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in three health systems.
Per Med
; 20(4): 357-374, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37577962
10.
Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation.
Per Med
; 20(4): 305-319, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37623911
11.
Cost-effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries.
Per Med
; 20(4): 321-338, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37746727
12.
Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies.
Per Med
; 20(4): 401-411, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37694556
13.
Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.
Per Med
; 20(4): 339-355, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37665240
14.
Cost-effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries.
Per Med
; 20(4): 387-399, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37665262
15.
Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young.
Per Med
; 20(4): 375-385, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37694384
16.
Ultrasonographic measurements of the prostate gland in castrated adult dogs.
Acta Vet Scand
; 64(1): 15, 2022 Jul 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35804438
17.
Costs of Persons with Dementia Living in Nursing Homes in The Netherlands.
J Alzheimers Dis
; 89(1): 359-366, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35871348
18.
Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.
Appl Health Econ Health Policy
; 20(4): 501-524, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35368231
19.
Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer.
Drugs Real World Outcomes
; 9(2): 275-285, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35314962
20.
Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision.
Pharmacoeconomics
; 39(4): 383-397, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33604870